RT Journal
A1 Wolf AD, Volk RJ
T1 REcommendations on use of prostate-specific antigen for prostate cancer screening—reply
JF JAMA
JO JAMA
YR 2012
FD April 4
VO 307
IS 13
SP 1372
OP 1374
DO 10.1001/jama.2012.397
UL http://dx.doi.org/10.1001/jama.2012.397
AB 
Garnick notes that the USPSTF concluded the “routine” use of PSA for prostate cancer screening should no longer be recommended. Had that indeed been the case, we would be in general agreement with the USPSTF's recommendation. But the critical point is that the USPSTF made a D recommendation—arguing there was moderate certainty that the harms of PSA-based screening outweigh the benefits and recommending against screening altogether. We suggested the evidence supports a C recommendation, wherein men would have the opportunity to make a decision about screening in consultation with their physician. This difference is not trivial because it affirms a physician's obligation to engage men in an informed decision-making process and provide the opportunity to make an individualized decision.